Primary Tumor Radiotherapy Omitting Clinical Target Volume for Patients With Advanced Non Small Cell Lung Cancer Responded to Immunotherapy and Chemotherapy
Status: Recruiting
Location: See location...
Intervention Type: Radiation
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
The aim of this randomized study is to investigate pneumonitis, local tumor control, and survival outcomes of primary tumor radiotherapy omitting CTV for patients with advanced NSCLC responded to immunotherapy and chemotherapy
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• Histologically or cytologically confirmed advanced non-small cell lung cancer (according to the 8th edition of the TNM cancer staging system of AJCC and UICC);
• After over two cycles of chemotherapy combined with immunotherapy, the efficacy was CR, PR or SD (with a decreasing trend);
• Age 18 to 80 years old, performance status 0-1;
• measurable or evaluable lesions;
• Survival expectancy is not less than 6 months;
• adequate cardiac, pulmonary, renal, and hepatic and bone marrow function
Locations
Other Locations
China
Hubei Cancer Hospital
RECRUITING
Wuhan
Contact Information
Primary
Guang Han, PhD
hg7913@hotmail.com
+86 13886048178
Time Frame
Start Date: 2024-03-13
Estimated Completion Date: 2027-10-08
Participants
Target number of participants: 134
Treatments
Experimental: CTV-omitted
CTV was omitted for primary tumor radiotherapy for advanced NSCLC who responded to therapy with immunotherapy and chemotherapy.
Active_comparator: CTV-delineated
CTV was delineated for primary tumor radiotherapy for advanced NSCLC who responded to induction therapy with immunotherapy and chemotherapy.
Related Therapeutic Areas
Sponsors
Leads: Hubei Cancer Hospital